Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 3/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 5/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30185810 | 0.98 | ALDH1A1 (0.55) | ALDH1A1TSHRLMNAKDM5AKDM4A | |
| SCHEMBL19852484 | 0.98 | ALDH1A1 (0.55) | ALDH1A1TSHRLMNAKDM5AKDM4A | |
| SCHEMBL4766606 | 0.94 | ALDH1A1 (0.43) | ALDH1A1TSHRLMNAKDM5AALOX5 | |
| SCHEMBL24703880 | 0.89 | ALDH1A1 (0.42) | ALDH1A1TSHRLMNAKDM5AALOX5 | |
| SCHEMBL29991123 | 0.87 | ALDH1A1 (0.41) | ALDH1A1LMNAKDM5AKDM4AKDM4C | |
| SCHEMBL5117460 | 0.85 | ALDH1A1 (0.37) | ALDH1A1TSHRLMNA | |
| SCHEMBL22205611 | 0.84 | LMNA (0.44) | ALDH1A1TSHRLMNAKDM5AALOX5 | |
| SCHEMBL23529660 | 0.81 | KDM5A (0.39) | ALDH1A1LMNAKDM5AKDM4AKDM4C | |
| SCHEMBL13552252 | 0.81 | PAOX (0.41) | ALDH1A1LMNAKDM5AALOX5KDM4A | |
| SCHEMBL499152 | 0.81 | GPR84 (0.39) | ALDH1A1LMNAKDM5AALOX5KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025034858-A1 | FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100168243-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100168243-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100168243-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| WO-2008156816-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156831-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156816-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | ALDH1A1 1991/4885TSHR 4303/4885LMNA 3400/4885 |
| US-20100168243-A1 | Renin Inhibitors | ACE, REN, DNPEP | ALDH1A1 1991/4885TSHR 4303/4885LMNA 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.